Navigation Links
Innovaderm Executes Multi-Year Enterprise Agreement with Medrio
Date:2/12/2019

Innovaderm Research, Inc., an innovative clinical research organization (CRO) specializing in dermatology, has finalized a deal to extend their use of Medrio, the leading provider of eClinical technology for early-phase pharma, medical device, and diagnostics clinical trials, through 2023. The CRO has been a regular Medrio customer for over nine years, primarily using the software in Phase I, Phase IIA, or Phase IIB pharma studies. With the new agreement, Innovaderm will continue to have access to a host of resources that will better enable them to deliver sponsor satisfaction and grow their business.

The agreement signifies Medrio’s status as a preferred electronic data capture (EDC) provider at Innovaderm. “We’ve long experienced consistent satisfaction from study sponsors when using Medrio,” commented Eric Hardy, Director of Data Management and Statistics at Innovaderm. “We recommend working with Medrio to our sponsor clients, particularly in early phase trials, and when given the discretion to choose the EDC for our trials, we favor Medrio.”

Innovaderm cited numerous factors in their decision to commit to this significant extension of their relationship with Medrio. These factors include:

  •     The high performance of the Medrio system in early phase pharma studies
  •     The flexibility and functionality of Medrio EDC
  •     Medrio’s ability to offer high-quality products and services at a low total cost of ownership – a key benefit for organizations conducting early phase studies

“The success of Innovaderm is a perfect example of why Medrio delivers the most benefit in early phase clinical trials,” said Mike Novotny, founder and CEO at Medrio. “With this new agreement, we look forward to continuing to serve one of our longest-tenured customers as they help their sponsor clients bring innovative medical products to market.”

About Innovaderm Research, Inc.
Innovaderm Research is a prominent Contract Research Organization (CRO) specialized in Dermatology and focused on clinical studies of phase I, II, III & IV. Founded in 1999, the company provides a broad range of services including study design, protocol development, site selection and patient recruitment, regulatory and ethics submissions, clinical trial management, clinical monitoring, data management, biostatistics, medical monitoring and medical writing. Innovaderm prides itself on managing its activities in accordance to current Good Clinical Practice (GCP) from the International Conference of Harmonization (ICH), and being fully compliant to major international regulations such as the FDA (USA), Health Canada, EMA (Europe). For further information, please visit http://www.innovaderm.ca.

About Medrio
Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company's cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit http://www.medrio.com.

Read the full story at https://www.prweb.com/releases/innovaderm_executes_multi_year_enterprise_agreement_with_medrio/prweb16095890.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Rosetta Genomics Executes Credentialing Agreement with Three Rivers Provider Network
2. Alexandria Real Estate Equities, Inc. Executes 15-Year Lease Extension with NIH for 60,000 RSF of Mission-Critical Space at Alexandrias 9800 Medical Center Drive Campus in Shady Grove Life Sciences Center
3. Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets
4. CollPlant Executes Non-binding Term Sheet to Develop and Commercialize a Novel Product for Spinal Fusion and Trauma Indications in Collaboration with Leading US Partner
5. MabVax Therapeutics Holdings Executes a Debt Facility for up to $10 million
6. Spherix Executes Joint Venture Agreement
7. Epsilon Signs New Multi-Year Agreement To Provide Global Database Marketing Services For Worldwide Biotechnology Leader Shire
8. DuPont Joins Israel’s Office of the Chief Scientist Global Enterprise R&D Cooperation Framework
9. Cambridge Semantics to Present the Case for Unified Information Access at Enterprise Data World 2013
10. NanoSight, One of the UKs Fastest Growing Biotechnology Companies, Wins a 2013 Queens Award for Enterprise - Innovation
11. Dik Barsamian Joins the US HealthConnect Inc. Group of Companies as the New President of Its CME Enterprises
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/4/2019)... ... April 03, 2019 , ... ... off-the-record collaboration and dialogue, today announces its Boston CEO conference to be held ... the industry’s challenges and opportunities with high-level panels and discussions from past, present ...
(Date:3/27/2019)... ... , ... In honor of National Nutrition Month, Lajollacooks4u has collaborated with the ... good nutrition. This month, Chef Jodi Abel appeared on two segments on KUSI’s ... first segment addressed the nutritional value of USDA’s MyPlate, a nutrition guide that simplifies ...
(Date:3/23/2019)... ... March 22, 2019 , ... Tosoh Bioscience LLC is ... detector , offering a revolutionary approach for the measurement of molecular weight (MW) ... novel optical design, a unique cell-block assembly, and a new calculation methodology make ...
(Date:3/19/2019)... ... 2019 , ... Bogey was nine years old when he injured both of his cruciate ligaments. ... ailments caused Bogey to experience problems with his mobility. According to his owners, he ... spot on the couch. , His owners, devastated at the sight of Bogey in so ...
Breaking Biology Technology:
(Date:3/27/2019)... ATLANTA (PRWEB) , ... March 26, 2019 , ... ... firm Greenberg Traurig, LLP , was a panelist at the National Academy of ... at NAS’ Keck Center. Holden, a member of the firm’s award-winning Pharmaceutical, Medical ...
(Date:3/26/2019)... FORT WORTH, Texas (PRWEB) , ... March 26, ... ... marketing plans to achieve corporate objectives for the company’s products and services. In ... blog on lifecyclebio.com, maintain and further develop the company’s website and customer beneficial ...
(Date:3/25/2019)... ... March 25, 2019 , ... ... a contract research organisation focused on advancing drug discovery, have announced a collaboration ... , Tissue clearing methods, which are essential to get a better view of ...
Breaking Biology News(10 mins):